TY - JOUR T1 - Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing the COVID-19 Related Cytokine Storm, ARDS and Mortality JF - In Vivo JO - In Vivo SP - 3027 LP - 3028 DO - 10.21873/invivo.12135 VL - 34 IS - 5 AU - KAREL SMETANA, JR. AU - DANIEL ROSEL AU - JAN BRÁBEK Y1 - 2020/09/01 UR - http://iv.iiarjournals.org/content/34/5/3027.abstract N2 - The FDA-approved drugs raloxifene and bazedoxifene could be among the best candidates to prevent mortality in severe COVID-19 patients. Raloxifene and bazedoxifene inhibit IL-6 signaling at therapeutic doses, suggesting they have the potential to prevent the cytokine storm, ARDS and mortality in severe COVID-19 patients, as is being shown with humanized antibodies blocking IL-6 signaling. In addition, raloxifene and bazedoxifene are selective estrogen receptor modulators with strong antiviral activity. ER -